Rein Therapeutics Inc.
RNTX
$1.40
-$0.08-5.41%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.69% | -39.00% | -1.88% | 22.07% | 100.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.75% | -4.60% | 42.84% | 83.16% | 132.31% |
| Operating Income | 19.75% | 4.60% | -42.84% | -83.16% | -132.31% |
| Income Before Tax | -106.66% | -140.65% | -247.70% | -309.53% | -125.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.38% | -134.53% | -239.15% | -299.71% | -125.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.38% | -134.53% | -239.15% | -299.71% | -125.97% |
| EBIT | 19.75% | 4.60% | -42.84% | -83.16% | -132.31% |
| EBITDA | 19.49% | 4.19% | -43.78% | -84.18% | -133.42% |
| EPS Basic | 15.43% | 17.09% | 10.41% | -2.30% | -9.30% |
| Normalized Basic EPS | 67.96% | 67.46% | 61.89% | 42.52% | -18.04% |
| EPS Diluted | 15.43% | 17.09% | 10.41% | -2.30% | -9.30% |
| Normalized Diluted EPS | 67.96% | 67.46% | 61.89% | 42.52% | -18.04% |
| Average Basic Shares Outstanding | 72.31% | 138.41% | 284.51% | 289.11% | 200.83% |
| Average Diluted Shares Outstanding | 72.31% | 138.41% | 284.51% | 289.11% | 200.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |